Mutter, ManfredTuchscherer, Gabriele2007-07-312007-07-312007-07-312006https://infoscience.epfl.ch/handle/20.500.14299/9990The invention discloses a method for the manuf. of a peptidic folding precursor (switch-peptide) stable and sol. at physiol. conditions, derived from a peptide having a potential for self-assembling and fibrillogenesis. Another object of the invention is to provide a tool for the quant., controlled in vitro study of fibrillogenesis and its inhibition of peptides involved in degenerative diseases. Prepn. of peptides is described.Functional groups (Nvoc; switch-peptides for study of fibrillogenesis and for drug screening)Enzymes Role: BUU (Biological use unclassified)CAT (Catalyst use)BIOL (Biological study)USES (Uses) (Phenacylase; switch-peptides for study of fibrillogenesis and for drug screening)Oligomers Role: ADV (Adverse effect including toxicity)BSU (Biological study unclassified)PRP (Properties)BIOL (Biological study) (and plaques; switch-peptides for study of fibrillogenesis and for drug screening)Peptides Role: BUU (Biological use unclassified)PRP (Properties)THU (Therapeutic use)BIOL (Biological study)USES (Uses) (compds.; switch-peptides for study of fibrillogenesis and for drug screening)Disease (degenerative; switch-peptides for study of fibrillogenesis and for drug screening)Proteins Role: ADV (Adverse effect including toxicity)BSU (Biological study unclassified)BIOL (Biological study) (huntingtin; switch-peptides for study of fibrillogenesis and for drug screening)Polymerization (oligomerization; switch-peptides for study of fibrillogenesis and for drug screening)Solid phase synthesis (peptide; switch-peptides for study of fibrillogenesis and for drug screening)AggregationChemical libraryConformationConformational transitionDrug screeningFibrilPhotolysisSelf-assemblypHbeta-Sheet (switch-peptides for study of fibrillogenesis and for drug screening)Prion proteins Role: ADV (Adverse effect including toxicity)BSU (Biological study unclassified)BIOL (Biological study) (switch-peptides for study of fibrillogenesis and for drug screening)Amino acids Role: BSU (Biological study unclassified)BIOL (Biological study) (switch-peptides for study of fibrillogenesis and for drug screening)Enzymes Role: BUU (Biological use unclassified)CAT (Catalyst use)BIOL (Biological study)USES (Uses) (switch-peptides for study of fibrillogenesis and for drug screening)Peptides Role: BUU (Biological use unclassified)PRP (Properties)THU (Therapeutic use)BIOL (Biological study)USES (Uses) (switch-peptides for study of fibrillogenesis and for drug screening)Acyl groups (transfer; switch-peptides for study of fibrillogenesis and for drug screening)Amyloid Role: ADV (Adverse effect including toxicity)BSU (Biological study unclassified)BIOL (Biological study) (beta-; switch-peptides for study of fibrillogenesis and for drug screening)degenerative diseasedrug screeningswitch peptideself assemblyfibrillogenesispatentUS2010152418EP1907416WO2006136906WO2006136906WO200613690637331126